Could an ingredient's degradation products need a different assessment from the original ingredient?

Could an ingredient's degradation products need a different assessment from the original ingredient?

The company publishes no study of degradation products.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sponsor-supplied sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names. The company publishes no repeated-dose study, no chronic study, no genotoxicity study, no cumulative-exposure estimate and no extrapolation from one population to another, and it does not offer an acute result as any of those.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.